Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 103, Issue 6, 2009, Pages 613-619

  van Griensven, Johan ^a   Zachariah, Rony ^b   Rasschaert, Freya ^b   Atté, Edi F ^a   Reid, Tony ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

Author keywords

Africa; Body weight; HIV; Lipoatrophy; Stavudine; Substitution

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PRIMARY HEALTH CARE; QUESTIONNAIRE; RWANDA; SCORING SYSTEM; URBAN AREA; WEIGHT GAIN; WEIGHT REDUCTION;

ADENINE; ADULT; ANTI-HIV AGENTS; BODY WEIGHT; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; PHOSPHONIC ACIDS; RWANDA; STAVUDINE; TREATMENT OUTCOME; WEIGHT LOSS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67349273843     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2008.08.015     Document Type: Article

References (27)

1. Grinspoon R., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected patients. N Engl J Med 352 (2005) 48-62
2. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 42 (2006) 562-571
3. Justman J.E., Hoover D.R., Shi Q., Tan T., Anastos K., Tien P.C., et al. Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr 47 (2008) 312-319
4. Wohl D.A., McComsey G., Tebas P., Brown T.T., Glesby M.J., Reeds D., et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 43 (2006) 645-653
5. Boulle A., Orrell C., Kaplan R., Van Cutsem G., McNally M., Hilderbrand K., et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral treatment in a large South African cohort. Antivir Ther 12 (2007) 753-760
6. Murphy R.A., Sunpath H., Kuritzkes D.R., Venter F., and Gandhi R.T. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 196 (2007) S449-S456
7. WHO. Report on WHO/UNAIDS meeting on forecasting ARV needs up to 2010. 7-8 November 2005. Geneva: World Health Organization; 2005. www.who.int/hiv/amds/ReportForecastingMeeting.pdf [accessed 21 July 2008].
8. WHO. Antiretroviral treatment for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. 2006 Revision. Geneva: World Health Organization; 2006. http://www.who.int/hiv/pub/guidelines/adult/en/index.html [accessed 21 July 2008]
9. Carr A., Miller J., Law M., and Cooper D.A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14 (2000) 25-32
10. Lichtenstein K.A., Ward D.J., Moorman A.C., Delaney K.M., Young B., Palella F.J., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 27 (2001) 1389-1398
11. Mallon P., Miller J., Cooper D.A., and Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17 (2003) 971-979
12. Brown T.T., Chu H., Wang Z., Palella F.J., Kingsley L., Witt M.D., et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 21 (2007) 1731-1738
13. Tien P.C., Schneider M.F., Cole S.R., Justman J.E., French A.L., Young M., et al. Relation of stavudine discontinuation to anthropometric changes among HIV-infected women. J Acquir Immune Defic Syndr 44 (2007) 43-48
14. van Griensven J., De Naeyer L., Mushi T., Ubarijoro S., Gashumba D., Gazille C., et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 101 (2007) 793-798
15. McComsey G.A., Ward D.J., Hessenthaler S.M., Sension M.G., Shalit P., Lonergan J.T., et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38 (2004) 263-270
16. Médecins Sans Frontières. Antiretroviral therapy in primary healthcare: Scaling-up in two health centres in Kigali, Rwanda. Brussels: Médecins Sans Frontières; 2007. http://www.msf.org/source/countries/africa/rwanda/2007/MSF_Rwanda%20capitalisation_final.pdf [accessed 21 July 2008]
17. Gerrior J.L., and Neff L.M. Nutrition assessment in HIV infection. Nutr Clin Care 8 (2005) 6-15
18. Subbaraman R., Chaguturu S.K., Mayer K.H., Flanigan T.P., and Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 15 (2007) 1093-1101
19. Carr A., Emery S., Law M., Puls R., Lundgren J.D., and Powderly W.G. An objective case definition in HIV-infected adults: a case-control study. Lancet 361 (2003) 726-735
20. McComsey G, Riordan M, Storer N, Goldman S, Ganz J, Libutti D, et al. Clinical lipoatrophy assessment strongly correlates with DEXA-measured limb fat and subcutaneous fat mitochondrial DNA levels. In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver. Abstract 751. http://www.retroconference.org/2006/Abstracts/26736.HTM [accessed 21 July 2008].
21. Martin A., Smith D.E., Carr A., Ringland C., Amin J., Emery S., et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18 (2004) 1029-1036
22. Moyle G.J., Sabin C.A., Cartledge J., Johnson M., Wilkins E., Churchill D., et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20 (2006) 2043-2050
23. Mangili A., Murman D.H., Zampini A.M., and Wanke C.A. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis 42 (2006) 836-842
24. Kennedy N., Ramsay A., Uiso L., Gutmann J., Ngowi F.I., and Gillespie S.H. Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania. Trans R Soc Trop Med Hyg 90 (1996) 162-166
25. Wools-Kaloustiana K., Kimaiyo S., Diero L., Siika A., Sidle J., Yiannoutsos C.T., et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20 (2006) 41-48
26. Ananworanich J., Nuesch R., Côté H.C., Kerr S.J., Hill A., Jupimai T., et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. J Antimicrob Chemother 61 (2008) 1340-1343
27. Mutimura E., Stewart A., and Crowther N.J. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther 4 (2007) 19